NCT00159796View on ClinicalTrials.gov

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

PHASE3CompletedINTERVENTIONAL
Enrollment

489

Participants

Timeline

Start Date

December 14, 2004

Primary Completion Date

March 28, 2006

Study Completion Date

April 28, 2006

Conditions
Bipolar Disorder
Interventions
DRUG

Asenapine

Asenapine, 3 weeks

DRUG

Olanzapine

Olanzapine, 3 weeks

DRUG

Placebo

placebo, 3 weeks

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00159796 - 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009) | Biotech Hunter | Biotech Hunter